ONCOLOGY remembers Dr Franco Muggia's contribution to cancer care.
Mike Hennessy Sr
Advertisement
Articles by Mike Hennessy Sr
B-cell maturation antigen target shows promise for patients with relapsed/refractory multiple myeloma.
The Chairman and founder of MJH Life Sciences discusses the current issue of ONCOLOGY®,
While the development of immunotherapy and targeted agents has advanced treatment options for a variety of malignancies, there is still the reminder that not all regimens work in treating cancer.
Advertisement
Latest Updated Articles
Finding The TargetPublished: August 12th 2020 | Updated:
ONCOLOGY Remembers Dr Franco MuggiaPublished: October 14th 2021 | Updated:
Forging Ahead in the COVID-19 eraPublished: July 15th 2020 | Updated:
Ensuring Decisional CapacityPublished: June 16th 2020 | Updated:
Optimizing Therapies For Patients With Lung CancerPublished: December 7th 2020 | Updated:
Choosing the Right PathPublished: September 22nd 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
FDA Approves Revumenib in R/R NPM1-Mutant AML
3
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
4
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
5
